semaglutide with type 1 diabetes semaglutide - Semaglutide type 1 diabetesreddit Type Exploring the Potential of Semaglutide in Type 1 Diabetes Management

Semaglutidein adultswith type 1 diabetesand obesity The landscape of diabetes treatment is continually evolving, and recent research is shedding light on the potential role of semaglutide in managing type 1 diabetes (T1D). While primarily known for its efficacy in treating type 2 diabetes and aiding in weight loss, emerging studies suggest that this GLP-1 receptor agonist, marketed under brand names like Ozempic and Wegovy, may offer considerable benefits for individuals with T1D, particularly those who are also overweight or obese.Semaglutideis atypeof medication you might need to take if you havetype2diabetesor prediabetes.

Semaglutide is a medication that mimics the action of a natural hormone called glucagon-like peptide-1 (GLP-1). This hormone plays a crucial role in regulating blood sugar levels by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and promoting satiety. For individuals with type 1 diabetes, where the pancreas produces little to no insulin, the application of semaglutide is a subject of ongoing investigation.

Glycemic Control and Weight Management in Type 1 Diabetes

A significant area of interest is semaglutide's impact on glycaemic control and weight in adults with type 1 diabetes, especially in the context of obesity.Semaglutide withdrawal in adults with type 1 diabetes on ... Multiple clinical trials and studies have indicated promising results. For instance, some research suggests that semaglutide can lead to a significant reduction in body weight, with studies noting approximately 11% of weight loss in individuals with excess weight. This is further supported by findings that weekly semaglutide improves blood sugar and weight in adults with Type 1 diabetes.

Furthermore, evidence points towards semaglutide improving glycemic metrics, including lowering HbA1c levels. Some studies have reported mean reductions in HbA1c ranging from -0.New clinical trial looking for participants to test ...20% to -0Semaglutide (subcutaneous route) - Side effects & dosage - Mayo Clinic.60%. Beyond average blood sugar levels, semaglutide has also shown to improve time spent in glycemic range and reduce glycaemic variability. This enhanced stability in blood sugar levels is a critical aspect of managing T1D. In some cases, the initiation of semaglutide shortly after diagnosis has been associated with a significant reduction in insulin dosage, with some newly diagnosed type 1 diabetes patients needing little or no insulin.

The study "Semaglutide in Adults with Type 1 Diabetes and Obesity" by VN Shah, published in 2025, highlights that semaglutide treatment has been associated with improved glycemia and weight loss without an increased incidence of hypoglycemia. Another study by S Madsbad in 2025 reiterates that both semaglutide and tirzepatide have been shown to improve glycaemic control.

Potential Benefits for Insulin Dosing and Kidney Function

Beyond direct glucose management and weight, semaglutide may also influence insulin requirements. Research indicates that semaglutide can produce rapid, sustained, and primarily bolus-driven insulin dose reductions, with early effects being largely independent of automated insulin delivery systems. This suggests a potential for decreased insulin requirements in individuals with T1D when using semaglutide.

Another area of active investigation is the effect of semaglutide on kidney function in individuals with type 1 diabetes.Effect of low dose Semaglutide in people with Type 1 ... Trials are exploring how Ozempic (semaglutide) affects kidney function in people who have type 1 diabetes and chronic kidney disease. The hypothesis is that semaglutide may reduce total daily insulin dose and improve glycemic variability without increasing the risk of severe hypoglycemia or diabetic ketoacidosis (DKA). This line of research is crucial, as kidney complications are a significant concern for individuals with long-standing diabetes.

Considerations and Cautions

It is important to note that the efficacy and safety of semaglutide in adults with type 1 diabetes are still under investigation, and the drug is not currently approved for this indicationSemaglutide Benefits Adults With Type 1 Diabetes + Obesity. While studies have shown positive outcomes, careful monitoring is essential. The use of semaglutide in type 1 diabetes should be managed by healthcare professionals who can assess individual patient needs and risksEfficacy of Semaglutide in Overweight and Obese Patients .... Potential side effects, such as nausea, vomiting, and diarrhea, are common with GLP-1 receptor agonists.2023年10月27日—Studies have shown thatsemaglutide can lower glycated hemoglobin (HbA1c) by 0.3 to 0.5%, with weight loss comparable to that observed in people ... Furthermore, some sources indicate that semaglutide should not be used in patients with certain conditions, including gastroparesis.

Existing evidence demonstrates that semaglutide (Ozempic) or tirzepatide (Mounjaro) have the potential to lower A1c, increase time-in-range, and reduce body weight. Studies like the "SMILE Trial" are actively testing semaglutide in people with type 1 diabetes, with hopes of demonstrating its ability to improve blood sugar levels. The NCT05819138 trial plans to learn more about the effects of semaglutide on cardiovascular function, kidney function, and insulin sensitivity in adults with Type 1 Diabetes.

In conclusion, while semaglutide has established its place in managing type 2 diabetes and obesity, its potential role in type 1 diabetes is an exciting frontier in endocrinology. The observed benefits in glycaemic control, weight management, and potential reduction in insulin needs warrant continued research and clinical evaluation to fully understand and harness its therapeutic possibilities for individuals living with Type 1 Diabetes.After treatment with semaglutide, newly diagnosed Type 1 ... Semaglutide may exert significant metabolic benefits in patients with established T1DM, and its off-label use alongside tirzepatide shows promise in type 1 diabetes.